Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 4/2010

01-08-2010 | Consensus Report

Italian consensus statement on paediatric HIV infection

Authors: C. Giaquinto, M. Penazzato, R. Rosso, S. Bernardi, O. Rampon, P. Nasta, A. Ammassari, A. Antinori, R. Badolato, G. Castelli Gattinara, A. d’Arminio Monforte, M. De Martino, A. De Rossi, P. Di Gregorio, S. Esposito, F. Fatuzzo, S. Fiore, A. Franco, C. Gabiano, L. Galli, O. Genovese, V. Giacomet, A. Giannattasio, C. Gotta, A. Guarino, A. Martino, F. Mazzotta, N. Principi, M. B. Regazzi, P. Rossi, R. Russo, M. Saitta, F. Salvini, S. Trotta, A. Viganò, G. Zuccotti, G. Carosi, The Italian Paediatric HIV Infection Working Group

Published in: Infection | Issue 4/2010

Login to get access

Abstract

The objective of this document is to identify and reinforce current recommendations concerning the management of HIV infection in infants and children in the context of good resource availability. All recommendations were graded according to the strength and quality of the evidence and were voted on by the 57 participants attending the first Italian Consensus on Paediatric HIV, held in Siracusa in 2008. Paediatricians and HIV/AIDS care specialists were requested to agree on different statements summarizing key issues in the management of paediatric HIV. The comprehensive approach on preventing mother-to-child transmission (PMTCT) has clearly reduced the number of children acquiring the infection in Italy. Although further reduction of MTCT should be attempted, efforts to personalize intervention to specific cases are now required in order to optimise the treatment and care of HIV-infected children. The prompt initiation of treatment and careful selection of first-line regimen, taking into consideration potency and tolerance, remain central. In addition, opportunistic infection prevention, adherence to treatment, and long-term psychosocial consequences are becoming increasingly relevant in the era of effective antiretroviral combination therapies (ART). The increasing proportion of infected children achieving adulthood highlights the need for multidisciplinary strategies to facilitate transition to adult care and maintain strategies specific to perinatally acquired HIV infection.
Appendix
Available only for authorised users
Literature
1.
The Italian Register for HIV Infection in Children. Update report April 2009.
2.
Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–8.CrossRefPubMed
3.
Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, et al. Incidence of opportunistic and other infections in HIV-infected children in the ART era. JAMA. 2006;296:292–300.CrossRefPubMed
4.
Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J. 2003;22:635–41.CrossRefPubMed
5.
Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.CrossRefPubMed
6.
McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989–2001. J Acquir Immune Defic Syndr. 2005;38:488–94.CrossRefPubMed
7.
Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis. 2007;45:918–24.CrossRefPubMed
8.
Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, et al. Key questions in antiretroviral therapy: Italian consensus workshop (2005). J Antimicrob Chemother. 2006;57:1055–64.CrossRefPubMed
9.
The European Mode of Delivery Collaboration. Elective caesarian-section vs. vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035–39.
10.
The International Perinatal HIV Group. Mode of delivery and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. N Engl J Med. 1999;340:977–87.CrossRef
11.
Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS. 1998;12:205–10.CrossRefPubMed
12.
13.
European HIV in Obstetrics Group. Higher rates of post-partum complications in HIV infected than in uninfected women irrespective of mode of delivery. AIDS. 2004;18:933–8.CrossRef
14.
15.
European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458–65.CrossRef
16.
Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1- infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–94.PubMed
17.
Galli L, Puliti D, Chiappini E, Gabbiano C, Ferrarsi G, Mignone F, Vigano A, Giaquinto C, Genovese O, Anzi dei G, Badolato R Buffolato W, Maccabruni A, Salvini F, Cellini M, Ruggeri M, Manzionna M, Bernardi S, Tovo P, De Martino M on behalf of Italian Register for HIV infection in children. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? Clin Infect Dis 2009;48:1310–17.
18.
Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283:1167–74.CrossRefPubMed
19.
Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–80.CrossRefPubMed
20.
The Italian Register for HIV Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med. 2002;156:915–21.
21.
Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Bénifla JL, Delfraissy JF, et al. Perinatal HIV-1 transmission—interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA. 1998;280:55–60.CrossRefPubMed
22.
Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomized trial. JAMA. 2002;288:189–98.CrossRefPubMed
23.
Van Rompay KK, Greenier JL, Marthas ML, Otsyula MG, Tarara RP, Miller CJ, et al. Immediate zidovudine treatment protects simian immunodeficiency virus- infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995;39:125–31.PubMed
24.
Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine [lett]. Science. 1995;270:1197–9.CrossRefPubMed
25.
Böttiger D, Johansson NG, Samuelsson B, Zhang H, Putkonen P, Vrang L, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS. 1997;11:157–62.CrossRefPubMed
26.
Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–14.CrossRefPubMed
27.
Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Bénifla JL, Burgard M, et al. Lamivudine–zidovudine combination for prevention on maternal–infant transmission of HIV-1. JAMA. 2001;285:2083–93.CrossRefPubMed
28.
Guay GE, Urban M, Chersich MF, Bolton C, van Niekerk R, Violari A, Stevens W, McIntyre JA; for the PEP Study Group. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child transmission on infants of untreated mothers. AIDS 2005;19:1289–97.
29.
Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982–91.CrossRefPubMed
30.
31.
Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996;335:1621–9.CrossRefPubMed
32.
Read JS, American Academy of Pediatrics, Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. Pediatrics. 2003;112:1196–205.CrossRefPubMed
33.
Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. 2006;55:1–17.
34.
Havens PL, Mofenson LM, American Academy of Pediatrics, Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics. 2008;122:1127–34.CrossRef
35.
Fiscus SA, Schoenbach VJ, Wilfert C. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 1999;340:1040–1.CrossRefPubMed
36.
Read JS, Committee on Pediatric AIDS, American Academy of Pediatrics. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics. 2007;120:1547–62.CrossRef
37.
European Collaborative Study. Increased risk of adverse pregnancy outcomes in ART-treated HIV-infected women in Europe. AIDS. 2004;17:2337–9.
38.
Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy. Supplement to PHSTF Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. PHSTF, 2004. http://​aidsinfo.​nih.​gov.
39.
Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS. 2003;17:2053–61.CrossRefPubMed
40.
European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1 infected mothers. AIDS. 2004;18:2009–17.CrossRef
41.
Townsend C, Schulte J, Thorne CL, Dominguez K, Cortina Borja M, Packham CS, Bohannon B, Tookey P. Exploring heterogeneity in the association between HAART and prematurity in three observational studies. 13th Observational workshop on Observational databases, Lisbon 26–28 March 2009.
42.
Noguera A, Fortuny C, Muñoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics. 2004;114:598–604.CrossRef
43.
Ekouevi DK, Touré R, Becquet R, Viho I, Sakarovitch C, Rouet F, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics. 2006;118:1071–7.CrossRef
44.
Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084–9.CrossRefPubMed
45.
Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003;22:782–9.CrossRefPubMed
46.
Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS. 2001;15:1074–5.CrossRefPubMed
47.
Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann N Y Acad Sci. 2000;918:236–46.CrossRefPubMed
48.
The European Collaborative Study. Hospitalization of children born to human immunodeficiency virus infected women in Europe. Pediatr Infect Dis J. 1997;16:1151–6.CrossRef
49.
Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398–404.CrossRefPubMed
50.
Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915–24.CrossRefPubMed
51.
52.
Ometto L, De Forni D, Patiri F, Trouplin V, Mammano F, Giacomet V, et al. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS. 2002;16:839–49.CrossRefPubMed
53.
The European Collaborative Study. Age-related standards for T lymphocytes subsets based on uninfected children born to HIV-infected women. Pediatr Infect Dis J. 1992;11:1018–26.CrossRef
54.
Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005;192:296–302.CrossRefPubMed
55.
De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis. 2002;186:312–20.CrossRefPubMed
56.
Bagnarelli P, Vecchi M, Burighel N, Bellanova D, Menzo S, Clementi M, et al. Genotypic and phenotypic correlates of the HIV type 1 env gene evolution in infected children with discordant response to antiretroviral therapy. AIDS Res Hum Retrovir. 2004;20:1306–13.CrossRefPubMed
57.
Patel K, PENTA group 219 study team, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46:1751–60.CrossRefPubMed
58.
Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Gattinara GC, et al. Changing patterns of clinical events inperinatally HIV-1 infected children during the era of HAART. AIDS. 2007;21:1607–15.CrossRefPubMed
59.
60.
61.
Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM, on behalf of the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5:61–86.CrossRefPubMed
62.
Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A, et al. HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Therapy. 2008;13:47–55.
63.
Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Bernardi S, et al. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine. 2008;26:5196–201.CrossRefPubMed
64.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.CrossRefPubMed
65.
Fraaij PL, Rakhmanina N, Burger D, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit. 2004;26:122–6.CrossRefPubMed
66.
HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20:1289–94.CrossRef
67.
Newell ML, Patel D, Goetghebuer T, Thorne C, European Collaborative Study. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis. 2006;193:954–62.CrossRefPubMed
68.
Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, Firtion G, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis. 2004;39:1692–8.CrossRefPubMed
69.
Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS. 2006;20:207–15.CrossRefPubMed
70.
Van der Linden D, Hainaut M, Goetghebuer T, Haelterman E, Schmitz V, Maes P, et al. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J. 2007;26:359–61.CrossRefPubMed
71.
Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debre M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004;18:237–245.
72.
Goetghebuer T, Haelterman E, Le Chenadec J, Dolfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009;23:597–604.CrossRefPubMed
73.
Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44.CrossRefPubMed
74.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283–96.
75.
Emery S, SMART Study Group and INSIGHT. Major clinical outcomes in patients not treated with antiretroviral therapy at baseline in SMART: a rationale for a trial to examine early treatment of HIV disease [Abstract WEPEB018]. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, 2007.
76.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al. Rate of AIDS diseases or death in HIV infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717–2721.CrossRefPubMed
77.
Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, et al. Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947–55.CrossRefPubMed
78.
DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038–46.CrossRefPubMed
79.
Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958–66.CrossRefPubMed
80.
Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;332:179–80.
81.
Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40:468–74.CrossRefPubMed
82.
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N, Wilson CM; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Prevalence of primary HIV drug resistance among recently infected adolescents: a multicenter Adolescent Trials Network study: ATN 029. 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, CO. Abstract # 21.
83.
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
84.
Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:61.CrossRef
85.
Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18:682–9.CrossRefPubMed
86.
Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271–9.CrossRefPubMed
87.
Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175–82.CrossRefPubMed
88.
Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR, et al. Adolescent Medicine HIV/AIDS Research Network. Barriers to ART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249–55.CrossRefPubMed
89.
Gibb DM on behalf of the PENTA 11 team. Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA 11 trial). J Int AIDS Soc. 2008;11, abs 021.
90.
Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS. 2008;22:749–57.CrossRefPubMed
91.
92.
Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115:488–94.CrossRef
93.
Esposito S, Bojanin J, Porta A, Cesati L, Gualtieri L, Principi N. Discontinuation of secondary prophylaxis for Pneumocystis Pneumonia in human immunodeficiency virus–infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:1117–20.CrossRefPubMed
94.
Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340:1301–6.CrossRefPubMed
95.
Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001;344:168–74.CrossRefPubMed
96.
Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001;20:40–8.CrossRefPubMed
97.
The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325:73–80.
98.
Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994;331:1181–7.CrossRefPubMed
99.
Moss WJ, Clements CJ, Halsey NA. Immunization of children, at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81:61–70.PubMed
100.
Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 2003;21:S35–7.CrossRefPubMed
101.
Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol. 2006;78:440–5.CrossRefPubMed
102.
Moss WJ, Clements CJ, Halsey NA. Immunization of children, at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81:61–70.PubMed
103.
European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443–51.CrossRef
104.
DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723–35.
105.
Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198:1599–608.CrossRefPubMed
106.
Vigano A, Giacomet V, Pattarino G, Fasan S, Zuccotti G, Brambilla P. Metabolic complications of HIV infection and its therapy in children. Futur HIV Therapy. 2007;1:181–90.CrossRef
107.
Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2005;90:4075–80.CrossRef
108.
Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antivir Ther. 2007;12:297–302.PubMed
109.
Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27:30–4.PubMed
110.
Viganò A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10:917–24.PubMed
111.
Charakida M, Tousoulis D, Skoumas I, Pitsavos C, Vasiliadou C, Stefanadi E, et al. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2009;204:532–7.CrossRefPubMed
112.
Viganò A, Cerini C, Meroni L, Giacomet V, Fabiano V et al. Long term HIV infection is associated with increased carotid intima media thickness in HIV infected adolescents. 16th Conference on Retroviruses and Opportunistic Infections, Montreal 2009, Abstract 915.
113.
Lester P, Chesney M, Cooke M, Weiss R, Whalley P, Perez B, et al. When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children. J Acquir Immune Defic Syndr. 2002;3:309–17.
114.
Instone SL. Perceptions of children with HIV infection when not told for so long: implications for diagnosis disclosure. J Pediatr Health Care. 2000;14:235–43.PubMed
115.
Bachanas PJ, Kullgren KA, Schwartz KS, Lanier B, McDaniel JS, Smith J, et al. Predictors of psychological adjustment in school-age children infected with HIV. J Pediatr Psychol. 2001;26:343–52.CrossRefPubMed
116.
Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection. Pediatr Infect Dis J. 2006;25:432–7.CrossRefPubMed
117.
Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health. 1999;25:316–9.CrossRefPubMed
118.
Giacomet V, Albano F, Starace F, de Franciscis A, Giaquinto C, Gattinara GC, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr. 2003;92:1398–402.CrossRefPubMed
Metadata
Title
Italian consensus statement on paediatric HIV infection
Authors
C. Giaquinto
M. Penazzato
R. Rosso
S. Bernardi
O. Rampon
P. Nasta
A. Ammassari
A. Antinori
R. Badolato
G. Castelli Gattinara
A. d’Arminio Monforte
M. De Martino
A. De Rossi
P. Di Gregorio
S. Esposito
F. Fatuzzo
S. Fiore
A. Franco
C. Gabiano
L. Galli
O. Genovese
V. Giacomet
A. Giannattasio
C. Gotta
A. Guarino
A. Martino
F. Mazzotta
N. Principi
M. B. Regazzi
P. Rossi
R. Russo
M. Saitta
F. Salvini
S. Trotta
A. Viganò
G. Zuccotti
G. Carosi
The Italian Paediatric HIV Infection Working Group
Publication date
01-08-2010
Publisher
Urban and Vogel
Published in
Infection / Issue 4/2010
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-010-0020-5

Other articles of this Issue 4/2010

Infection 4/2010 Go to the issue

Brief Report

Antibiotic treatment can be safely stopped in asymptomatic patients with prosthetic joint infections despite persistent elevated C-reactive protein values

Clinical and Epidemiological Study

Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules

Editorial

Prosthetic joint infections: what to do if the C-reactive protein level remains elevated

Clinical and Epidemiological Study

Prognostic factors of the mortality of postoperative intraabdominal infections

Clinical and Epidemiological Study

Clinical manifestations of dengue and leptospirosis in children in Mumbai: an observational study

Clinical and Epidemiological Study

Monitoring of perceptions, anticipated behavioral, and psychological responses related to H5N1 influenza
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits